“`html
10/26/2025 – 08:30 PM
Milan and New York – Genenta Science (GNTA), a biopharmaceutical firm specializing in immuno-oncology, has announced a registered direct offering expected to generate gross proceeds of approximately $15.0 million. The deal, finalized on October 27, 2025, involves the sale of 4,285,715 American Depositary Shares (ADSs) to institutional investors at a price of $3.50 per ADS, before deducting placement agent fees and other offering expenses.
Maxim Group LLC served as the lead placement agent, with Rodman & Renshaw LLC acting as the co-placement agent for the offering.
According to the company release, Genenta plans to allocate the net proceeds towards bolstering its working capital and for general corporate purposes. The offering is anticipated to close on or around October 28, 2025, contingent upon customary closing conditions, offering investors a stake in a company betting on novel cancer treatments. Specifically, the funds may be utilized to advance Genenta’s ongoing clinical trials and explorations of its Temferon technology, hinting at a strategic move to accelerate its research and development initiatives.
The offering is being made under a shelf registration statement on Form F-3 (File No. 333-271901) previously filed with the U.S. Securities and Exchange Commission (SEC), which was declared effective on May 24, 2023. A prospectus supplement related to the securities will be filed with the SEC.
About Genenta Science
Genenta Science (GNTA) is a clinical-stage immuno-oncology company. The company’s lead product candidate, Temferon™, aims to leverage hematopoietic stem cells to deliver immune-therapeutic payloads directly into the tumor microenvironment. This approach is designed to create a targeted and durable anti-cancer response. Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients and has initiated a Phase 1/2a metastatic Renal Cell Carcinoma study, evaluating Temferon in combination with immune checkpoint inhibitors. Temferon’s design positions it as a potential monotherapy and as a combination therapy to amplify the effectiveness of existing treatments.
The market is closely watching Genenta’s progress, given the rising demand for more effective cancer therapies. The company’s focus on genetically modified hematopoietic stem cells, and its ability to deliver payloads directly to malignant tumors is a novel approach that is markedly different than current approaches. The completion of Phase I clinical trials is promising, but further investigation is warranted and needs to be studied.
Forward-Looking Statements
This press release contains forward-looking statements subject to risks and uncertainties, as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and assumptions that could be inaccurate, including the closing, timing, and size of the offering, the company’s use of proceeds, and the progress of clinical trials. Risks associated with these statements are detailed in Genenta’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC. The discussed product candidates are under clinical evaluation, and their safety or effectiveness has not been established. Temferon™ is an investigational product not approved for use in any jurisdiction.
FAQ
What did Genenta (GNTA) announce on October 27, 2025?
Genenta announced a registered direct offering of 4,285,715 ADSs at $3.50 each for gross proceeds of about $15.0 million.
When is the Genenta (GNTA) offering expected to close?
The offering is expected to close on or about October 28, 2025, subject to customary closing conditions.
How does Genenta (GNTA) plan to use the proceeds from the $15.0 million offering?
Genenta intends to use the net proceeds for working capital and general corporate purposes.
Were warrants or derivative securities issued in Genenta’s (GNTA) offering?
No; all securities were sold by Genenta and no warrants or other derivative securities were issued in connection with the offering.
Under what registration is Genenta (GNTA) conducting the offering?
The securities are being offered under a previously declared effective Form F-3 (File No. 333-271901), with a prospectus supplement to be filed with the SEC.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/11641.html
